Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.69 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14424026 | 0.88 | SIGMAR1 (0.71) | SIGMAR1TAAR1AOC3SLC6A2SLC6A4 | |
| SCHEMBL27885210 | 0.83 | SIGMAR1 (0.65) | SIGMAR1TAAR1AOC3KDM4E | |
| SCHEMBL19954175 | 0.83 | SIGMAR1 (0.65) | SIGMAR1TAAR1AOC3KDM4EADRA2B | |
| SCHEMBL19498804 | 0.82 | KDM4E (0.81) | SIGMAR1TAAR1AOC3KDM4EADRA2B | |
| SCHEMBL19498789 | 0.82 | SIGMAR1 (1.00) | SIGMAR1TAAR1AOC3KDM4EADRA2B | |
| SCHEMBL18711188 | 0.81 | KCNH2 (0.47) | SIGMAR1TAAR1AOC3KDM4EHTR2A | |
| SCHEMBL7141888 | 0.80 | SIGMAR1 (0.61) | SIGMAR1TAAR1AOC3KDM4E | |
| SCHEMBL11740957 | 0.80 | TAAR1 (0.58) | SIGMAR1TAAR1AOC3KDM4ESLC6A2 | |
| SCHEMBL19129470 | 0.80 | TAAR1 (0.58) | SIGMAR1TAAR1AOC3KDM4ESLC6A2 | |
| SCHEMBL14790515 | 0.79 | TAAR1 (0.64) | SIGMAR1TAAR1AOC3KDM4ESLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230174506-A1 | (DI)AMINATION OF ACTIVATED ALLENE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR SYNTHESIS OF THE SAME | PURDUE RESEARCH FOUNDATION | 2023-06-08 | — | — | US | disclosed |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20210002231-A1 | HYBRID MU OPIOID RECEPTOR AND NEUROPEPTIDE FF RECEPTOR BINDING MOLECULES, THEIR METHODS OF PREPARATION AND APPLICATIONS IN THERAPEUTIC TREATMENT | UNIVERSITÉ DE STRASBOURG (FR) | 2021-01-07 | — | — | US | disclosed |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-05 | — | — | US | disclosed |
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMAN-LA ROCHE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-7256186-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256186-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256199-B1 | Pyrimidone derivatives | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-08-14 | — | — | US | disclosed |
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | SIGMAR1 344/4885TAAR1 885/4885AOC3 78/4885 |
| US-20230174506-A1 | (DI)AMINATION OF ACTIVATED ALLENE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR SYNTHESIS OF THE SAME | NAAA, PAM, AANAT | SIGMAR1 2110/4885TAAR1 82/4885AOC3 18/4885 |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SIGMAR1 764/4885TAAR1 2181/4885AOC3 3525/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SIGMAR1 764/4885TAAR1 2181/4885AOC3 3525/4885 |
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | SIGMAR1 1928/4885TAAR1 2237/4885AOC3 4581/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | SIGMAR1 1928/4885TAAR1 2237/4885AOC3 4581/4885 |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | SIGMAR1 3521/4885TAAR1 4845/4885AOC3 2612/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | SIGMAR1 391/4885TAAR1 622/4885AOC3 104/4885 |
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | IDO1, ZC3HAV1, AZI2 | SIGMAR1 1329/4885TAAR1 1296/4885AOC3 412/4885 |
| US-20210002231-A1 | HYBRID MU OPIOID RECEPTOR AND NEUROPEPTIDE FF RECEPTOR BINDING MOLECULES, THEIR METHODS OF PREPARATION AND APPLICATIONS IN THERAPEUTIC TREATMENT | OPRL1, OPRM1, NPFFR1 | SIGMAR1 10/4885TAAR1 99/4885AOC3 2833/4885 |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SIGMAR1 764/4885TAAR1 2181/4885AOC3 3525/4885 |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | SIGMAR1 764/4885TAAR1 2181/4885AOC3 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.